Repositioning Candidate Details
| Candidate ID: | R0725 |
| Source ID: | DB05183 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | MLN0415 |
| Synonyms: | -- |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | MLN0415 is a novel, small molecule IKK2 inhibitor, discovered by Millennium scientists. In preclinical studies, MLN0415 was shown to decrease NF-kB activation and down-regulate the expression of a number of inflammatory proteins. Because inflammatory proteins play a critical role in inflammation and drive the inflammatory response to disease, controlling these proteins may prevent or slow disease progression. |
| CAS Number: | -- |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in inflammatory disorders (unspecified). |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | MLN0415 is an oral, highly selective, small molecule inhibitor of IKK2, which targets a major inflammatory pathway. MLN0415 was shown to decrease NF-kB activation and down-regulate the expression of a number of inflammatory proteins. Because inflammatory proteins play a critical role in inflammation and drive the inflammatory response to disease, controlling these proteins may prevent or slow disease progression. |
| Targets: | Inhibitor of nuclear factor kappa-B kinase subunit beta |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|